Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression signatures of TP53 mutations in serous ovarian cancers.

BMC cancer - 26 May 2010

Bernardini Marcus Q, Baba Tsukasa, Lee Paula S, Barnett Jason C, Sfakianos Gregory P, Secord Angeles Alvarez, Murphy Susan K, Iversen Edwin, Marks Jeffrey R, Berchuck Andrew

Abstract excerpt

BACKGROUND: Mutations in the TP53 gene are extremely common and occur very early in the progression of serous ovarian cancers. Gene expression patterns that relate to mutational status may provide insight into the etiology and biology of the disease. METHODS: The TP53 coding region was sequenced in 89 frozen serous ovarian cancers, 40 early stage (I/II) and 49 advanced stage (III/IV). Affymetrix U133A expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Staging
Share to Algorithms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cluster Analysis

Share to Oligonucleotide Array Sequence Analysis

Share to Ovarian Neoplasms

Share to Survival Analysis

Share to Survivors

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 20504346
DOI: 10.1186/1471-2407-10-237
PMCID: PMC2893110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression signatures of TP53 mutations in serous ovarian cancers.PMID 20504346Read ↗

TP53 mutations in epithelial ovarian cancerSemantic proximity Read ↗

TP53 Mutations in Breast and Ovarian Cancer.Semantic proximity Read ↗

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesSemantic proximity Read ↗

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.Semantic proximity Read ↗

Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Poor survival with wild-type TP53 ovarian cancer?Semantic proximity Read ↗

Targeted Genomic Sequencing Reveals Novel TP53 In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian CarcinomaSemantic proximity Read ↗

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.Semantic proximity Read ↗

Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.Semantic proximity Read ↗

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)Semantic proximity Read ↗

Optimized p53 immunohistochemistry is an accurate predictor of <i>TP53</i> mutation in ovarian carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.